阿托伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者外周血ROCK2激酶活性及肺动脉压力的影响

目的：探讨口服阿托伐他汀片对慢性阻塞性肺疾病（chronic obstructive pulmonary Disease，COPD）合并肺动脉高压（pul-monary hypertension，PH）患者外周血ROCK2激酶活性及肺动脉压力的影响。方法：选取COPD合并PH患者60例为研究对象，并将其随机分为对照组（给予吸氧、抗感染、化痰、平喘等基础治疗）和阿托伐他汀治疗组（在基础治疗的基础上给予阿托伐他汀片20mg／d治疗）；随访观察周期12周，于试验开始前和结束后检测外周血ROCK2的活性，利用彩色多普勒检测肺动脉压力的变化，肺功能变化（测定FEV1，FVC）。结果：与对照组比较，阿托伐他汀治疗可显著降低患者血浆中ROCK2的水平（P〈0．01）；降低患者的肺动脉压力，改善患者的肺功能（FEV1，FVC），P均〈0．05。结论：在常规吸氧、抗感染等治疗的基础上，联合应用阿托伐他汀可显著降低ROCK2激酶的活性和肺动脉压力，从而改善肺功能。

The Effects of Atorvastatin on ROCK2-kinase Activity and Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease and Pulmonary Hvoertension

Objective： To investigate the effect of oral administration of atorvastatin on the ROCK-kinase activity and pulmonary artery pressure level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Methods： Sixty patients with chronic obstructive pulmonary disease and pulmonary hypertension were selected and divided into two groups, the control group and ator- vastatin treatment group, 30 patients in each group. The patients in control group were given the basic treatment, such as oxygen, anti-infection, dissipate phlegm and anti-wheeze therapy et al. The patients in atorvastatin treatment group were given the oral administra- tion of atorvastatin 20 mg on the basis of treatments. The observation period was 12 weeks. The plasma levels of ROCK 2 in patients, the pulmonary artery pressure and the variation of pulmonary function were detected before and after treatment. Results： Compared with the control group, the plasma levels of ROCK2 was much lower in atorvastatin treatment group. And the atorvastatin treatment decreased the pulmonary artery pressure improves the pulmonary pressure levels more significantly than the basic treatment. Conclusions： Based on the basic treatment, the plus of atorvastatin could lower the ROCK2 kinase activities and decrease the pulmonary artery pressure and im- prove pulmonary function.